OIS XIII SPONSORS
Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
Stuart Therapeutics is a clinical stage company developing therapeutics for ophthalmic indications based on the company's platform technology, the PolyCol family of collagen mimetic peptides, or CMPs. This first in class therapeutic approach targets damaged extracellular matrix collagen for repair, restoring both structure and healthy cell signaling. The mechanism of action has a pronounced effect on epithelial and neuronal cell health, and has been shown to reduce inflammation in a variety of disease models. The company is developing CMPs to treat diseases of the anterior and posterior segment, as well as certain refractory indications.
Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.
Ace Vision Group
Ace Vision Group, Inc, (“AVG” or “the Company”) is an emerging ophthalmic laser device company focused on bringing innovative touchless Eye Laser Therapy to patients suffering from age-related vision loss.
The Company is focused on the development and commercialization of its first product, the VisioLite® Ophthalmic Laser, a touchless therapeutic device.
The initial use for this device is Laser Scleral Microporation® (LSM), an innovative, clinical stage, minimally invasive rejuvenation therapy for the treatment of presbyopia, and potentially other eye diseases including glaucoma.
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders.
Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company’s first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and is the first off-the-shelf, clinically validated cell therapy for corneal care, having received regulatory approval in Japan. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. To learn more about Aurion Biotech, visit www.aurionbiotech.com
Harrow and it’s affiliate Imprimis are focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable. These pharmaceutical products are used in the U.S. in ophthalmic surgical procedures, such as cataract and refractive surgeries, as well as large and growing chronic eyecare markets, such as dry eye disease, glaucoma, allergies, and infections. Harrow and Imprimis currently serve over 10,000 doctors, hospitals, and ambulatory service centers through an integrated national sales and customer service organization and efficient, scalable, and tech-enabled national production and distribution platforms licensed to do business in all 50 U.S. states.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our robust product pipeline positions Ocular Therapeutix to become a leader in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current standard of care by developing sustained release alternatives. With a focus on advancing our products through to Phase 3 clinical trials, our intention is to develop a commercially viable portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing for better patient outcomes.
Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline includes: OCS-01, a topical candidate in Phase 3 for diabetic macular edema and inflammation and pain following ocular surgery; OCS-02, a topical biologic candidate in Phase 2b for dry eye disease and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophthalmic disorders. Headquartered in Switzerland and with operations in the US, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team and supported by leading international healthcare investors.
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.
Nyxol is being developed for several indications including pharmacologically-induced mydriasis, presbyopia, and dim light or night vision disturbances. Nyxol is an investigational 505(b)(2) product candidate that has been studied in over 650 subjects across 12 completed Phase 1, 2, and 3 trials.
Our second product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema.
APX3330 has been studied in over 340 patients across six Phase 1 and five Phase 2 trials.
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD. ONL1204, the Company's lead compound, is currently being used in three Phase 1b studies in the indications of retinal detachment, Geographic Atrophy and Open Angle Glaucoma. The Company is preparing to enter Phase 2 studies in the same indications.
Re-Vana Therapeutics is a pioneering ocular drug delivery and therapeutic company focused on developing the world’s first ocular sustained-release biologics to be delivered in the office. Our innovative platform technologies, EyeLief®, EyeLief SD™, and OcuLief®, enable the efficient delivery of biologics and small molecules, expanding global treatment opportunities. With a multi-billion-dollar market segment,
our non-surgical approach offers a significant advantage over traditional treatments.
We have two parallel strategies in place. Internal sustained release biologic development and external strategic collaborations with major pharma companies.
After raising $3.25 million in a pre-Series A round in 2020, Re-Vana successfully closed a Series A round worth $11.9 million in November 2022. Leading US ophthalmic-focused VC's, Visionary Ventures, ExSight Ventures, and InFocus Capital, as well as UK investors and a corporate investor, participated
in this round.
Trefoil Therapeutics is a clinical stage company focused on the application of a novel engineered FGF-1 compound (TTHX1114) in underserved ophthalmic disease areas. The lead indication is the treatment of corneal edema associated with endothelial dysfunction. Trefoil also has a topical formulation in development for for the treatment of epithelial dysfunction associated with Sjogren’s Syndrome. Trefoil has completed a phase 2 clinical study for the intracameral injectable formulation and a phase 1 safety study for the topical formulation.
ViaLase, Inc. is a globally-minded, venture capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. ViaLase is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care. With a leadership team that has vast experience developing, designing, manufacturing, and commercializing the first femtosecond lasers for ophthalmic surgery for refractive and cataract patients, ViaLase is now bringing that expertise and innovation to glaucoma patients. ViaLase believes in collaborating closely with health care providers, payers, societies, and patients to inform our product development and commercial activities with the goal of bringing this revolutionary treatment to glaucoma patients across the globe.
Oyster Point Pharma, Inc. is now a part of Viatris. Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories.